Delivery Order SPE2DB20D9226-SPE2DB23FQ61C

Award Date 9/11/23
Potential Completion Date 10/2/23
Potential Value $3.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $3,094.80 and an ultimate completion date of February 3, 2025. DMS Pharmaceutical Group Inc. also holds a significant single-award Indefinite...
This federal contract award is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order with a firm fixed price type and has a ceiling value of $7,737. The contract does not have a set-aside designation. DMS Pharmaceutical Group Inc....
This federal contract award is for the delivery of XOLAIR 300 MG/2 ML SYRINGE 2ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $27,907.20, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract is a firm fixed-price delivery order, with a completion date of January 30, 2025. DMS Pharmaceutical Group Inc. has been a key supplier to the DLA, holding a $499,999,999...
This federal contract award is for the delivery of XOLAIR 75 MG/0.5 ML AUTOINJECT 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $3,405.36, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program,...
This federal contract award is for the delivery of XOLAIR 150 MG/ML syringes to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,547.40, was awarded to DMS Pharmaceutical Group Inc., a for-profit woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract, contract...
This federal contract award is for the delivery of XOLAIR 150 MG/ML SYRINGEML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $4,642.20 and an ultimate completion date of October 10, 2024. It is part of a larger...
This federal contract award is for the delivery of XOLAIR 150 MG/1.2 ML POWDER VLS to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $19,838.64 and is a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth up to $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/mL syringes, with a period of performance through April 18, 2024. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, number SPE2DB, valued at up to $4,999,999 through the end of 2025, which allows DLA to issue firm fixed-price...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,547.40 firm fixed-price delivery order is for the supply of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a specialized pharmaceutical product. The contract is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB...
This contract award is for the delivery of XOLAIR 150 MG/ML syringes to the Defense Logistics Agency (DLA), a U.S. Department of Defense agency. The contract, valued at $4,642.20, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has an ultimate completion date of February 20, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery...
  • SPE2DB20D9226
    Indefinite Delivery Contract
  • SPE2DB20D9226-SPE2DB23FQ61C
    Delivery Order

This federal contract award is for the delivery of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract, valued at up to $3,868.50, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois.

DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 and running through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The current award is a delivery order issued under this larger IDC contract vehicle.

Generated 1/9/25, 9:23 AM